In a significant advance in diabetes treatment, drugmaker Eli Lilly said today that its experimental pill, orforglippon, produced dramatic results in a late-stage study — bringing new hope to millions of type 2 diabetes and obesity patients. The drug, a once-daily tablet, is in the GLP-1 receptor agonist class — the same family as injectable […]